Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PHVS Pharvaris N.V.

休市中 07-11 16:00:00 EDT

25.12

+5.29

+26.68%

盘后25.00

-0.12-0.48%

19:30 EDT

最高25.76	最低19.80	成交量15.58万
今开20.00	昨收19.83	日振幅30.06%
总市值13.69亿	流通市值5.33亿	总股本5,449万
成交额351.76万	换手率0.73%	流通股本2,123万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":25.12,"timestamp":1752264000000,"preClose":19.83,"halted":0,"volume":155804,"hourTrading":{"tag":"盘后","latestPrice":25,"preClose":25.12,"latestTime":"19:30 EDT","volume":842,"amount":21009.8501,"timestamp":1752276652881},"delay":0,"floatShares":21230522,"shares":54493142,"eps":-3.041696,"marketStatus":"休市中","change":5.29,"latestTime":"07-11 16:00:00 EDT","open":20,"high":25.76,"low":19.8,"amount":3517607.318324,"amplitude":0.300555,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.041696,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":19.83,"preHourTrading":{"tag":"盘前","latestPrice":20.04,"preClose":19.83,"latestTime":"09:27 EDT","volume":807,"amount":17397.554556,"timestamp":1752240470061},"postHourTrading":{"tag":"盘后","latestPrice":25,"preClose":25.12,"latestTime":"19:30 EDT","volume":842,"amount":21009.8501,"timestamp":1752276652881},"volumeRatio":4.551387279692483},"requestUrl":"/m/hq/s/PHVS","defaultTab":"news","newsList":[{"id":"2550676824","title":"Pharvaris N.V.盘中异动 股价大涨5.41%报19.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550676824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550676824?lang=zh_cn&edition=full","pubTime":"2025-07-11 03:36","pubTimestamp":1752176193,"startTime":"0","endTime":"0","summary":"北京时间2025年07月11日03时36分，Pharvaris N.V.股票出现异动，股价快速上涨5.41%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.69%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071103363397a14fef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071103363397a14fef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2548002362","title":"Pharvaris N.V.盘中异动 早盘急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548002362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548002362?lang=zh_cn&edition=full","pubTime":"2025-07-01 21:35","pubTimestamp":1751376933,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日21时35分，Pharvaris N.V.股票出现波动，股价大幅下跌5.00%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.03%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012135339795f614&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012135339795f614&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2546725815","title":"Pharvaris N.V.盘中异动 下午盘股价大跌5.31%报16.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546725815","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546725815?lang=zh_cn&edition=full","pubTime":"2025-06-28 01:46","pubTimestamp":1751046370,"startTime":"0","endTime":"0","summary":"北京时间2025年06月28日01时46分，Pharvaris N.V.股票出现异动，股价急速下挫5.31%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.43%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280146109791a93a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280146109791a93a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2545449736","title":"Pharvaris N.V.盘中异动 快速跳水5.36%报17.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545449736","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545449736?lang=zh_cn&edition=full","pubTime":"2025-06-24 00:54","pubTimestamp":1750697655,"startTime":"0","endTime":"0","summary":"北京时间2025年06月24日00时54分，Pharvaris N.V.股票出现异动，股价大幅跳水5.36%。截至发稿，该股报17.03美元/股，成交量7726股，换手率0.01%，振幅3.90%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.20%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624005415a4b991d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624005415a4b991d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2545170725","title":"Pharvaris N.V.盘中异动 股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170725","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545170725?lang=zh_cn&edition=full","pubTime":"2025-06-21 03:50","pubTimestamp":1750449056,"startTime":"0","endTime":"0","summary":"北京时间2025年06月21日03时50分，Pharvaris N.V.股票出现波动，股价急速上涨5.11%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.70%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621035056a7151662&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621035056a7151662&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2542342580","title":"Pharvaris N.V.盘中异动 早盘股价大涨7.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542342580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542342580?lang=zh_cn&edition=full","pubTime":"2025-06-11 21:31","pubTimestamp":1749648691,"startTime":"0","endTime":"0","summary":"北京时间2025年06月11日21时31分，Pharvaris N.V.股票出现异动，股价快速拉升7.01%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.13%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611213131a4a3957a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611213131a4a3957a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2542337597","title":"Pharvaris N.V.盘中异动 临近收盘股价大涨5.60%报17.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542337597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542337597?lang=zh_cn&edition=full","pubTime":"2025-06-10 03:56","pubTimestamp":1749498980,"startTime":"0","endTime":"0","summary":"北京时间2025年06月10日03时56分，Pharvaris N.V.股票出现波动，股价快速拉升5.60%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.62%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610035620977844e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610035620977844e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2541865508","title":"Pharvaris N.V.盘中异动 股价大涨7.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541865508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541865508?lang=zh_cn&edition=full","pubTime":"2025-06-06 22:00","pubTimestamp":1749218413,"startTime":"0","endTime":"0","summary":"北京时间2025年06月06日22时00分，Pharvaris N.V.股票出现异动，股价大幅上涨7.10%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.91%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606220013951171ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606220013951171ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2540706368","title":"Pharvaris N.V.盘中异动 大幅拉升7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540706368","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540706368?lang=zh_cn&edition=full","pubTime":"2025-06-04 00:31","pubTimestamp":1748968275,"startTime":"0","endTime":"0","summary":"北京时间2025年06月04日00时31分，Pharvaris N.V.股票出现异动，股价快速上涨7.02%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.27%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604003115a6f8e950&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604003115a6f8e950&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2539176261","title":"Pharvaris N.V.盘中异动 早盘急速拉升5.73%报16.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539176261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539176261?lang=zh_cn&edition=full","pubTime":"2025-05-29 23:01","pubTimestamp":1748530894,"startTime":"0","endTime":"0","summary":"北京时间2025年05月29日23时01分，Pharvaris N.V.股票出现异动，股价急速上涨5.73%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.80%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529230134a49183a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529230134a49183a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2537955935","title":"Pharvaris N.V.盘中异动 大幅跳水5.36%报16.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537955935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537955935?lang=zh_cn&edition=full","pubTime":"2025-05-22 02:29","pubTimestamp":1747852140,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日02时29分，Pharvaris N.V.股票出现异动，股价快速下挫5.36%。截至发稿，该股报16.33美元/股，成交量9830股，换手率0.02%，振幅3.42%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.99%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052202290094fe37c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052202290094fe37c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2536636914","title":"Pharvaris N.V.2025财年第一财季实现净利润-48.77百万美元，同比减少60.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536636914","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536636914?lang=zh_cn&edition=full","pubTime":"2025-05-20 00:00","pubTimestamp":1747670431,"startTime":"0","endTime":"0","summary":"5月20日，Pharvaris N.V.公布财报，公告显示公司2025财年第一财季净利润为-48.77百万美元，同比减少60.37%；其中营业收入为0.00美元，每股基本收益为-0.90美元。机构评级：截至2025年5月20日，当前有10家机构对Pharvaris N.V.目标价做出预测，其中目标均价为33.17美元，其中最低目标价为14.05美元，最高目标价为54.90美元。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000040a484439b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000040a484439b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS"],"gpt_icon":0},{"id":"2536803636","title":"Pharvaris N.V.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536803636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536803636?lang=zh_cn&edition=full","pubTime":"2025-05-19 21:42","pubTimestamp":1747662121,"startTime":"0","endTime":"0","summary":"北京时间2025年05月19日21时42分，Pharvaris N.V.股票出现异动，股价大幅跳水5.07%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.46%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519214201a6e4d314&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519214201a6e4d314&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2535071764","title":"Pharvaris N.V.盘中异动 早盘快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535071764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535071764?lang=zh_cn&edition=full","pubTime":"2025-05-14 22:56","pubTimestamp":1747234570,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日22时56分，Pharvaris N.V.股票出现波动，股价急速跳水5.03%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.43%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514225610a6df1b60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514225610a6df1b60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2532068044","title":"Pharvaris N.V.盘中异动 大幅上涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532068044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532068044?lang=zh_cn&edition=full","pubTime":"2025-05-01 00:12","pubTimestamp":1746029544,"startTime":"0","endTime":"0","summary":"北京时间2025年05月01日00时12分，Pharvaris N.V.股票出现异动，股价急速上涨5.39%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.02%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501001224974bc21e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501001224974bc21e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2530191131","title":"Pharvaris N.V.盘中异动 股价大涨5.15%报16.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530191131","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530191131?lang=zh_cn&edition=full","pubTime":"2025-04-25 21:32","pubTimestamp":1745587934,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日21时32分，Pharvaris N.V.股票出现波动，股价大幅上涨5.15%。截至发稿，该股报16.65美元/股，成交量223股，换手率0.00%，振幅0.00%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.47%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213214974517d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213214974517d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2530952658","title":"Pharvaris N.V.盘中异动 快速拉升5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530952658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530952658?lang=zh_cn&edition=full","pubTime":"2025-04-24 22:54","pubTimestamp":1745506468,"startTime":"0","endTime":"0","summary":"北京时间2025年04月24日22时54分，Pharvaris N.V.股票出现异动，股价大幅上涨5.20%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.67%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424225429aa2c7a4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424225429aa2c7a4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2529558457","title":"Pharvaris N.V.盘中异动 早盘急速拉升5.45%报15.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529558457","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529558457?lang=zh_cn&edition=full","pubTime":"2025-04-22 21:52","pubTimestamp":1745329920,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日21时52分，Pharvaris N.V.股票出现异动，股价大幅上涨5.45%。截至发稿，该股报15.29美元/股，成交量308股，换手率0.00%，振幅0.83%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.29%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422215200a6c3dfaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422215200a6c3dfaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2527244991","title":"Pharvaris N.V.盘中异动 股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527244991","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527244991?lang=zh_cn&edition=full","pubTime":"2025-04-15 22:58","pubTimestamp":1744729114,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日22时58分，Pharvaris N.V.股票出现异动，股价大幅拉升5.39%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.01%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415225834aa2c7009&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415225834aa2c7009&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2518979278","title":"Pharvaris N.V.盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518979278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518979278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613493,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Pharvaris N.V.股票出现波动，股价快速拉升5.26%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.59%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharvaris.com","stockEarnings":[{"period":"1week","weight":0.3505},{"period":"1month","weight":0.4733},{"period":"3month","weight":1.0933},{"period":"6month","weight":0.4112},{"period":"1year","weight":0.3772},{"period":"ytd","weight":0.3104}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pharvaris N.V.于2015年9月30日注册在荷兰成立。他们是一家临床阶段的生物制药公司，致力于针对尚未满足需求的罕见疾病的创新疗法的开发和商业化，最初的重点是血管性水肿和其他缓激肽介导的疾病。他们的第一个分子PHA121是新型的小分子缓激肽B2受体拮抗剂，可用于治疗遗传性血管性水肿或HAE。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005341},{"month":2,"riseRate":0,"avgChangeRate":-0.10879},{"month":3,"riseRate":0.4,"avgChangeRate":-0.042615},{"month":4,"riseRate":0.6,"avgChangeRate":0.04111},{"month":5,"riseRate":0.2,"avgChangeRate":-0.101468},{"month":6,"riseRate":0.6,"avgChangeRate":0.189847},{"month":7,"riseRate":0.4,"avgChangeRate":0.080825},{"month":8,"riseRate":0.75,"avgChangeRate":-0.047911},{"month":9,"riseRate":0.5,"avgChangeRate":-0.05778},{"month":10,"riseRate":0.25,"avgChangeRate":-0.063186},{"month":11,"riseRate":0.25,"avgChangeRate":-0.202488},{"month":12,"riseRate":0.5,"avgChangeRate":1.203802}],"exchange":"NASDAQ","name":"Pharvaris N.V.","nameEN":"Pharvaris N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pharvaris N.V.,PHVS,Pharvaris N.V.股票,Pharvaris N.V.股票老虎,Pharvaris N.V.股票老虎国际,Pharvaris N.V.行情,Pharvaris N.V.股票行情,Pharvaris N.V.股价,Pharvaris N.V.股市,Pharvaris N.V.股票价格,Pharvaris N.V.股票交易,Pharvaris N.V.股票购买,Pharvaris N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}